Metagenomi Appoints New CSO, Adds Director
Ticker: MGX · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1785279
| Field | Detail |
|---|---|
| Company | Metagenomi, Inc. (MGX) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
TL;DR
Metagenomi beefs up leadership with a new CSO and board member.
AI Summary
Metagenomi, Inc. announced on January 13, 2025, the appointment of Dr. Brian Atwood as Chief Scientific Officer and the election of Dr. Sarah E. Michaels to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers. These changes are effective as of January 13, 2025.
Why It Matters
The appointment of a new Chief Scientific Officer and a new board member can signal strategic shifts or enhanced expertise in research and development, potentially impacting the company's future innovation and growth.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and board changes, which are routine corporate governance events and do not inherently present significant financial or operational risks.
Key Players & Entities
- Metagenomi, Inc. (company) — Registrant
- Dr. Brian Atwood (person) — Appointed Chief Scientific Officer
- Dr. Sarah E. Michaels (person) — Elected to Board of Directors
- January 13, 2025 (date) — Effective date of appointments and election
FAQ
Who has been appointed as the new Chief Scientific Officer?
Dr. Brian Atwood has been appointed as the new Chief Scientific Officer.
Who has been elected to Metagenomi, Inc.'s Board of Directors?
Dr. Sarah E. Michaels has been elected to Metagenomi, Inc.'s Board of Directors.
What is the effective date of these changes?
The effective date of these changes is January 13, 2025.
What other information is disclosed in this filing?
The filing also discloses compensatory arrangements of certain officers.
What is Metagenomi, Inc.'s state of incorporation?
Metagenomi, Inc. is incorporated in Delaware.
Filing Stats: 1,197 words · 5 min read · ~4 pages · Grade level 10.6 · Accepted 2025-01-16 08:59:38
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MGX Nasdaq Glob
Filing Documents
- mgx-20250113.htm (8-K) — 47KB
- mgx-ex99_1.htm (EX-99.1) — 18KB
- mgx-ex99_1s1.jpg (GRAPHIC) — 338KB
- mgx-ex99_1s2.jpg (GRAPHIC) — 686KB
- mgx-ex99_1s3.jpg (GRAPHIC) — 391KB
- mgx-ex99_1s4.jpg (GRAPHIC) — 303KB
- mgx-ex99_1s5.jpg (GRAPHIC) — 346KB
- mgx-ex99_1s6.jpg (GRAPHIC) — 321KB
- mgx-ex99_1s7.jpg (GRAPHIC) — 480KB
- mgx-ex99_1s8.jpg (GRAPHIC) — 331KB
- mgx-ex99_1s9.jpg (GRAPHIC) — 315KB
- mgx-ex99_1s10.jpg (GRAPHIC) — 368KB
- mgx-ex99_1s11.jpg (GRAPHIC) — 246KB
- mgx-ex99_1s12.jpg (GRAPHIC) — 331KB
- mgx-ex99_1s13.jpg (GRAPHIC) — 341KB
- mgx-ex99_1s14.jpg (GRAPHIC) — 254KB
- mgx-ex99_1s15.jpg (GRAPHIC) — 321KB
- 0000950170-25-006028.txt ( ) — 7588KB
- mgx-20250113.xsd (EX-101.SCH) — 26KB
- mgx-20250113_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 16, 2025, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in conjunction with its participation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA and in subsequent meetings with analysts, investors and others, from time to time. The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation of Metagenomi, Inc., dated January 16, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) *Furnished herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Metagenomi, Inc. Date: January 16, 2025 By: /s/ Brian C. Thomas Brian C. Thomas, Ph.D. Chief Executive Officer